Holmium laser with Moses lasers for Kidney

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Kidney+1 More
Holmium laser with Moses lasers - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will compare the holmium laser with Moses versus the thulium laser in patients undergoing ureteroscopic laser lithotripsy for stone disease.

Eligible Conditions
  • Kidney

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 10 Secondary · Reporting Duration: approximately 8 weeks (1 month post-operative)

Month 1
Change in Quality of life survey (WISQOL short form) both pre-operatively and post-operatively
Stone free rate
Up to 6 hours
Score on the Laser Evaluation Instrument
Month 1
% of participants with post-operative complications
up to 6 hours
Fragmentation/dusting time (minutes)
Laser efficiency (mm per minute)
Lasing time (minutes)
Number of times the laser pedals are pressed
Procedural Time ( minutes)
Total energy used (kilojoules)
Total operative time (minutes)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Participants treated with Holmium laser with the Moses laser
1 of 2
Participants treated with Holmium laser with the thulium laser
1 of 2
Experimental Treatment

164 Total Participants · 2 Treatment Groups

Primary Treatment: Holmium laser with Moses lasers · No Placebo Group · Phase 4

Participants treated with Holmium laser with the Moses laser
Device
Experimental Group · 1 Intervention: Holmium laser with Moses lasers · Intervention Types: Device
Participants treated with Holmium laser with the thulium laser
Device
Experimental Group · 1 Intervention: Holmium laser with thulium lasers · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: approximately 8 weeks (1 month post-operative)

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor
1,061 Previous Clinical Trials
2,563,635 Total Patients Enrolled
Stephen Nakada, MDPrincipal InvestigatorUniversity of Wisconsin, Madison
3 Previous Clinical Trials
257 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 7th, 2021

Last Reviewed: October 4th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.